Trials / Completed
CompletedNCT01455415
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
A Study Of Pregabalin In The Treatment Of Subjects With Painful Diabetic Peripheral Neuropathy With Background Treatment Of Nsaid For Other Pain Conditions
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to test the effectiveness of pregabalin in treating nerve pain caused by diabetes. The suitable subjects will be patients who also use an non-steroid anti-inflammatory drug for another pain which is not related to the diabetic nerve pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin | 150 - 300 mg/day in divided dose (3 time a day) for 6 weeks |
| DRUG | placebo | matching placebo 3 time a day |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-11-01
- Completion
- 2013-12-01
- First posted
- 2011-10-20
- Last updated
- 2021-01-28
- Results posted
- 2015-04-23
Locations
61 sites across 4 countries: United States, Czechia, Italy, Sweden
Source: ClinicalTrials.gov record NCT01455415. Inclusion in this directory is not an endorsement.